<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62126">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01965236</url>
  </required_header>
  <id_info>
    <org_study_id>8985</org_study_id>
    <nct_id>NCT01965236</nct_id>
  </id_info>
  <brief_title>Influence of Sodium Intake on Left Ventricular-arterial Coupling</brief_title>
  <official_title>Influence of Sodium Intake on Left Ventricular-arterial Coupling in Hypertension: Biomechanical Assessment and Modelisation of Left Ventricular Function With Arterial Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present  study is to asses the effectiveness of the aorta-ventricular
      coupling according to low and high sodium intake in 28 controled hypertensive patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of left ventricular function in two groups of 13 patients according to their
      different salt's consumption in double blind and crossover study.  Performance  estimation
      of the left ventricle by echocardiographic and central arterial pressure by  tonometry.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>ultrasound volume, imaging &quot;strain&quot; and tonometry</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are given 5 placebo (microcrystalline cellulose) pills per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 pills (1 g per pill) of sodium chloride per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>sodium chloride</intervention_name>
    <description>Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertension stage 1, with medium or high risk, when the treatment (mono or therapy
             without diuretics) is efficient, when the great pressure is reached (&lt;140/90 mmHg)

          -  High sodium intake (sodium urinary excretion for 24h (UNaV) &gt; or = 170 mmol/24h
             before visit 0

          -  Limited sodium intake objective (UNaV&lt;85 mmol/24h)attempted at the end of the limited
             sodium intake period of 2 weeks

          -  Patients aged between 18 and 80 years

          -  Subject has given written informed consent

          -  Subject has subscribed a health care insurance

        Exclusion Criteria:

          -  Secondary hypertension

          -  Complications associated with the arterial hypertension : history of cardiovascular
             diseases or myocardial infarction, cerebrovascular accident, coronary disease, ...

          -  Arterial hypertension associated with cardiopathy

          -  Arterial hypertension associated with nephropathy

          -  Arterial hypertension associated with diabetes

          -  Measure of central arterial pressure by tonometry is impossible

          -  Cardiac echogenicity is not satisfactory for the analysis of left ventricular loop
             analysis

          -  Patient refuses informed consent

          -  Follow-up impossible for 15 weeks

          -  Pregnant or women without efficacy contraception

          -  Patient without freedom by administration decision

          -  Patient in exclusion period

          -  Patient without french insurance

          -  Adult protected by the law
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guilhem DU CAYLAR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of intern Medicine and arterial Hypertension Lapeyronie University Hospital of Montpellier, Montpellier, France, 34295</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guilhem DU CAYLAR, PhD</last_name>
    <phone>+33 4 67 33 84 43</phone>
    <email>g-du_caylar@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lapeyronie University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 17, 2013</lastchanged_date>
  <firstreceived_date>October 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension, sodium intake, left ventricular function</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
